Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient's liver ...

Danuglipron, a weight-loss pill, won’t continue its stages of testing after a person in a clinical trial was reportedly injured. Pfizer plans to explore other obesity treatments for testing. Pfizer is ...

Pfizer is an innovative pharmaceutical giant that investors have given up on, which is an opportunity if you think long-term.

Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver issues. The company said it halted development of danuglipron, an oral drug ...

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...